Patents Assigned to Yissum Research Development Company of the Hebrew University of Jerusalem
  • Publication number: 20250129033
    Abstract: Novel inhibitors of MetAp2 enzymatic activity and uses thereof are provided.
    Type: Application
    Filed: February 15, 2023
    Publication date: April 24, 2025
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ofra BENNY, Arie DAGAN
  • Publication number: 20250129380
    Abstract: The present invention, is directed to a method for selecting an improved genetically modified Solanum plant, the method including: determining the presence of at least one inactive allele of auxin responsive factor (ARF) 8 gene in the genome of the genetically modified Solanum plant or a part derived therefrom; and (b) selecting a genetically modified Solanum plant determined as having a genome including the at least one inactive allele of ARF8 gene, wherein the improvement is at least any one of: (i) increased yield; (ii) increased resistance to a pathogen; (iii) earlier fruit setting; and (iv) any combination of (i) to (iii), compared to a wild-type variant of said Solanum plant, thereby, selecting an improved genetically modified Solanum plant.
    Type: Application
    Filed: February 1, 2023
    Publication date: April 24, 2025
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization
    Inventors: Naomi ORI, Alon ISRAELI, Maya BAR
  • Publication number: 20250127167
    Abstract: The invention generally discloses short and ultrashort peptides with improved antimicrobial properties.
    Type: Application
    Filed: September 14, 2022
    Publication date: April 24, 2025
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventor: Meital RECHES
  • Publication number: 20250114303
    Abstract: The present invention relates to a method of determining the trapped volume and the trapped aqueous volume of a plurality of liposomes in a liposomal composition. The method can be used for calculating the concentration of an active pharmaceutical ingredient entrapped within the liposomes and for quality assurance of a pre-formed liposomal composition.
    Type: Application
    Filed: January 1, 2023
    Publication date: April 10, 2025
    Applicants: Moebius Medical Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel BARENHOLZ, Keren TURJEMAN, Ron PINKUS
  • Patent number: 12269977
    Abstract: The technology subject of the present application concerns a novel class of fused nanocrystal molecules having unique electronic properties. The application further contemplates methods for their preparation and methods of their use.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: April 8, 2025
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Uri Banin, Jiabin Cui, Yossi Panfil, Nir Waiskopf, Meirav Oded
  • Publication number: 20250092415
    Abstract: Disclosed herein are genetically modified plants having altered biological activity of 3-?-hydroxysteroid dehydrogenase/isomerase (GAME25), or 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plants have an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Further disclosed herein are genetically modified plants having altered expression of a gene encoding a 3-?-hydroxysteroid dehydrogenase/isomerase (GAME25), or a 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plant has an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof.
    Type: Application
    Filed: October 9, 2024
    Publication date: March 20, 2025
    Applicants: Yeda Research and Development Co. Ltd., Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
    Inventors: Asaph AHARONI, Prashant SONAWANE, Pablo D. CARDENAS, Saul BURDMAN
  • Publication number: 20250066769
    Abstract: Methods of treating fragile X syndrome by administering agents that reduce expression or function of various proteins are provided. Methods of determining suitability to be treated by the methods of the invention are also provided.
    Type: Application
    Filed: December 26, 2022
    Publication date: February 27, 2025
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventor: Nissim BENVENISTY
  • Patent number: 12226427
    Abstract: Methods of reactivating transcription of a fragile X mental retardation 1 (FMR1) gene and treating FMR1-associated diseases are provided. Compositions and kits for doing same are also provided.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: February 18, 2025
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Nissim Benvenisty, Dan Vershkov
  • Publication number: 20250049793
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAK1) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Application
    Filed: February 5, 2024
    Publication date: February 13, 2025
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yinon Ben-Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Int Snir-Alkalay, Joseph P. Vacca, Dansu Li
  • Patent number: 12214066
    Abstract: Provided are methods, compositions and kits employing cellulose nanocrystals for hair-straightening treatment. Also provided are methods, compositions and kits employing a resilin, for hair-straightening treatment and/or for maintenance of straightened hair following a hair-straightening treatment.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 4, 2025
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., SMART RESILIN LTD.
    Inventors: Oded Shoseyov, Roni Shalev, Sigal Baruch-Sharon, Tal Ben Shalom, Liron Nuttman-Nesial
  • Publication number: 20250025401
    Abstract: Provided are systems, compositions, methods and devices for manufacturing artificial skin substitutes and related products mimicking the morphology and appearance of human skin. Applications of the invention pertain to the fields of regenerative medicine and pharma with products that can support tissue replacement and tissue engineering. The most immediate applications pertain to the field of cosmetics with the development of pigmented compositions that can be incorporated in various skin care and cosmetic foundation products.
    Type: Application
    Filed: November 23, 2022
    Publication date: January 23, 2025
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Oded SHOSEYOV, Chen NOWOGRODSKI, Yaniv DAMATOV
  • Publication number: 20250009744
    Abstract: Methods of treating lipotoxicity in the lungs by administering a metabolic regulator are provided.
    Type: Application
    Filed: October 11, 2023
    Publication date: January 9, 2025
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Yaakov NAHMIAS, Avner EHRLICH
  • Publication number: 20250002435
    Abstract: The present invention provides arylated fenchone derivatives, compositions comprising them, processes for their preparation and uses thereof.
    Type: Application
    Filed: October 7, 2022
    Publication date: January 2, 2025
    Applicant: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
    Inventors: Raphael MECHOULAM (deceased), Reem SMOUM, Ruth GALLILY, Mona DVIR-GINZBERG
  • Patent number: 12182721
    Abstract: A method comprising: receiving, as input, training images, wherein at least a majority of the training images represent normal data instances; receiving, as input, a target image; extracting (i) a set of feature representations from a plurality of image locations within each of the training images, and (ii) target feature representations from a plurality of target image locations within the target image; calculating, with respect to a target image location of the plurality of target image locations in the target image, a distance between (iii) the target feature representation of the target image location, and (iv) a subset from the set of feature representations comprising the k nearest the feature representations to the target feature representation; and determining that the target image location is anomalous, when the calculated distance exceeds a predetermined threshold.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: December 31, 2024
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Yedid Hoshen, Liron Bergman, Niv Cohen, Tal Reiss
  • Patent number: 12161763
    Abstract: Provided is a formulation and method for increasing bioavailability of an orally administered drug.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: December 10, 2024
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Amnon Hoffman, Abraham J. Domb, Anna Elgart, Irina Cherniakov
  • Patent number: 12138265
    Abstract: Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9).
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: November 12, 2024
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
    Inventors: Irit Snir-Alkalay, Joseph P. Vacca, Yinon Ben-Neriah
  • Patent number: 12139421
    Abstract: A process for preparing a granular composite adsorbent, that includes combining poly(diallyl dimethyl ammonium halide) and a clay mineral in water, maintaining the mixture under stirring, recovering a wet mass, forming the wet mass into granules and drying the granules to obtain the granular adsorbent having surface layer with positive zeta potential. The granular material and methods using the granular material in water treatment are also disclosed.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: November 12, 2024
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Yael Mishael, Ofri Zusman, Mario Kummel
  • Publication number: 20240360408
    Abstract: A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.
    Type: Application
    Filed: July 11, 2024
    Publication date: October 31, 2024
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LT
    Inventor: Eduardo N. Mitrani
  • Publication number: 20240358711
    Abstract: Methods of inhibiting reactive oxygen species production by neutrophils or treating neutrophil-mediated inflammation in a subject by contacting the neutrophils with or administering an agent selected from a cyclin dependent kinase 4 (CDK4) inhibitor, a cyclin dependent kinase 6 (CDK6) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a proto-oncogene tyrosine-protein kinase Src (SRC) inhibitor and a sodium (Na) channel blocker are provided. Pharmaceutical compositions comprising a nanoparticle, the agent and a neutrophil targeting peptide are also provided.
    Type: Application
    Filed: July 28, 2022
    Publication date: October 31, 2024
    Applicants: IMMUNYX PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., Hadasit Medical Research Services and Development Ltd.
    Inventors: Seth Jonah SALPETER, Meital NAIM, Zvika GRANOT, Zvi Gregorio FRIDLENDER
  • Publication number: 20240350401
    Abstract: The disclosure concerns viscous or gelled delivery systems based on oily nano-domains dispersed in a viscosified/gelled continuous aqueous phase, and suitable for prolonged and/or sustained topical delivery of various active compounds.
    Type: Application
    Filed: June 27, 2024
    Publication date: October 24, 2024
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., LYOTROPIC DELIVERY SYSTEMS LTD
    Inventors: Nissim GARTI, Sharon GARTI LEVI